U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07132489) titled 'Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI' on Aug. 11.
Brief Summary: To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include:
HbA1c/C-peptide ratio
Albumin-bilirubin (ALBI) score.
Neutrophil/HDL ratio
Study Start Date: Sept. 01
Study Type: OBSERVATIONAL
Condition:
Myocardial Infarction
No Reflow Phenomenon
Intervention:
DIAGNOSTIC_TEST: HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
1. To investigate whethe...